Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

NCT03059797 PHASE2 COMPLETED

To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).

Details

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	PHASE2
Status	COMPLETED
Enrolment	120
Start date	Mon Mar 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Small Cell Lung Cancer

Interventions

• Anlotinib
• Placebo

Countries

China